Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• المؤلفون الرئيسيون: Antonio Lacquaniti (مؤلف), Patrizio Pasqualetti (مؤلف), Teresa Casuscelli di Tocco (مؤلف), Susanna Campo (مؤلف), Stefania Rovito (مؤلف), Maurizio Bucca (مؤلف), Antonino Ragusa (مؤلف), Paolo Monardo (مؤلف)
• التنسيق: كتاب
• منشور في: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...